Development of an integrated digital health intervention to promote engagement in and adherence to medication for opioid use disorder

Kirsten J Langdon, Susan Ramsey, Caroline Scherzer, Kate Carey, Megan L Ranney, Josiah Rich, Kirsten J Langdon, Susan Ramsey, Caroline Scherzer, Kate Carey, Megan L Ranney, Josiah Rich

Abstract

Background: Buprenorphine-naloxone is an evidence-based treatment for Opioid Use Disorder. However, despite its efficacy, nearly half of participants are unsuccessful in achieving stabilization (i.e., period of time following medication induction in which medication dose is adjusted to be effective in reducing cravings/withdrawal, minimize potential side effects, and eliminate illicit substance use). This paper presents the study design and protocol for a digital health intervention designed to promote engagement in and adherence to buprenorphine treatment, offered through an outpatient addiction treatment center, through motivational enhancement and distress tolerance skills training. Personalized feedback interventions represent a promising method to effectively motivate engagement in and adherence to buprenorphine treatment. These interventions are generally brief, individually tailored, and have the potential to be delivered via mobile platforms. Distress tolerance, a transdiagnostic vulnerability factor, has been implicated in the development and maintenance of substance use. Targeting distress tolerance may improve substance use treatment outcomes by promoting the ability to persist in goal-directed activity even when experiencing physical or emotional distress.

Methods: The study aims are to: (1) develop and refine an interactive computer- and text message-delivered personalized feedback intervention that incorporates distress tolerance skills training for persons who have elected to initiate outpatient buprenorphine treatment (iCOPE); (2) examine the feasibility, acceptability, and preliminary efficacy of iCOPE for increasing abstinence, adherence, and retention in treatment compared to a treatment as usual comparison condition; and, (3) examine potential mechanisms that may underlie the efficacy of iCOPE in improving outcomes, including motivation, distress tolerance, self-regulation, and negative affect.

Discussion: Results of this study will be used to determine whether to proceed with further testing through a large-scale trial. This work has the potential to improve treatment outcomes by reducing illicit opioid use, increasing adherence/retention, and preventing future overdose and other complications of illicit opioid use. Trial Registration NCT03842384.

Keywords: Buprenorphine; Distress tolerance; Medications for opioid use disorder; Mobile treatment; Motivational enhancement; Opioid use disorder.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Overview of Proposed iCOPE Intervention

References

    1. Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and opioid-involved overdose deaths–United States, 2013–2017. Morb Mortal Wkly Rep. 2018;67:1419–1427.
    1. 2017 National Survey on Drug Use and Health, Mortality in the United States; 2016.
    1. National Academies of Sciences, Engineering, and Medicine; 2019.
    1. Boothby LA, Doering PL. Buprenorphine for the treatment of opioid dependence. Am J Health Syst Pharm. 2007;64:266–272.
    1. Medication-Assisted Treatment Buprenorphine. In: Substance Abuse and Mental Health Services Administration. 2016. . Accessed 11 Nov 2019.
    1. Thomas CP, Fullerton CA, Kim M, Montejano L, Lyman DR, Dougherty RH, et al. Medication-assisted treatment with buprenorphine: assessing the evidence. Psychiatric Serv. 2014;65:158–170.
    1. Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction. 2014;109:79–87.
    1. Stein MD, Herman DS, Kettavong M, Cioe PA, Friedmann PD, Tellioglu T, et al. Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons. J Subst Abuse Treat. 2010;39:157–166.
    1. Novak A, Burgess ES, Clark M, Zvolensky MJ, Brown RA. Anxiety sensitivity, self-reported motives for alcohol and nicotine use, and level of consumption. J Anxiety Disord. 2003;17:165–180.
    1. McHugh RK, Kneeland ET. Affective vulnerability in substance use disorders. Curr Opin Psychol. 2019;30:54–58.
    1. Brown RA, Lejuez CW, Kahler CW, Strong DR. Distress tolerance and duration of past smoking cessation attempts. J Abnorm Psychol. 2002;111:180–185.
    1. Lejuez CW, Paulson A, Daughters SB, Bornovalova MA, Zvolensky MJ. The association between heroin use and anxiety sensitivity among inner-city individuals in residential drug use treatment. Behav Res Ther. 2006;44:667–677.
    1. Trafton JA, Gifford EV. Behavioral reactivity and addiction: the adaptation of behavioral response to reward opportunities. J Neuropsychiatry Clin Neurosci. 2008;20:23–35.
    1. McHugh RK, Otto MW. Profiles of distress intolerance in a substance-dependent sample. Am J Drug Alcohol Abuse. 2012;38:161–165.
    1. McHugh RK, Weiss RD, Cornelius M, Martel MO, Jamison RN, Edwards RR. Distress intolerance and prescription opioid misuse among patients with chronic pain. J Pain. 2016;17:806–814.
    1. Daughters SB, Lejuez CW, Bornovalova MA, Kahler CW, Strong DR, Brown RA. Distress tolerance as a predictor of early treatment dropout in a residential substance abuse treatment facility. J Abnormal Psychol. 2005;114(4):729.
    1. Strong DR, Brown RA, Sims M, Herman DS, Anderson BJ, Stein MD. Persistence during stress-challenge predicts lapse to opiate use during buprenorphine treatment. J Addiction Med. 2012;6:19–25.
    1. Daughters SB, Lejuez CW, Kahler CW, Strong DR, Brown RA. Psychological distress tolerance and duration of most recent abstinence attempt among residential treatment-seeking substance abusers. Psychol Addictive Behaviors. 2005;19(2):208.
    1. Bornovalova MA, Gratz KL, Daughters SB, Hunt ED, Lejuez CW. Initial RCT of a distress tolerance treatment for individuals with substance use disorders. Drug Alcohol Depend. 2012;122:70–76.
    1. Janis IL, Mann L. Decision-making: a psychological analysis of conflict, choice, and commitment. New York: The Free Press; 1997.
    1. Collins SE, Kirouac M, Lewis MA, Witkiewitz K, Carey KB. Randomized controlled trial of web-based decisional balance feedback and personalized normative feedback for college drinkers. J studies Alcohol Drugs. 2014;75(6):982–992.
    1. Lee CM, Neighbors C, Kilmer JR, Larimer ME. A brief, web-based personalized feedback selective intervention for college student marijuana use: a randomized clinical trial. Psychol Addict Behav. 2010;24:265–273.
    1. ; Accessed Jan 12, 2017.
    1. Head KJ, Noar SM, Iannarino NT, Harrington NG. Efficacy of text message-based interventions for health promotion: a meta-analysis. Soc Sci Med. 2013;97:41–48.
    1. Muench F, Weiss RA, Kuerbis A, Morgenstern J. Developing a theory driven text messaging intervention for addiction care with user driven content. Psychol Addictive Behavior. 2013;27:315–321.
    1. Onken LS, Carroll KM, Shoham V, Cuthbert BN, Riddle M. Re-envisioning clinical science: unifying the discipline to improve the public health. Clin Psychol Sci. 2014;2(1):22–34.
    1. Ritchie J, et al. Qualitative research practice: a guide for social science students and researchers. Tucson: Sage Publishing; 2013.
    1. Gale NK, et al. Using the framework method for the analysis of qualitative data in multidisciplinary health research. BMC Med Res Methodol. 2013;13:117.
    1. Smith J, Firth J. Qualitative data analysis: the framework approach. Nurse Res. 2011;18:52–62.
    1. Brooker J. Digital Equipment Co Ltd. United Kingdom: Reading; 1986.
    1. Bevan N, Kirakowski J, Maissel J. What is Usability? In: Bullinger H-J, editor. Human aspects in computing: design and use of interactive systems and work with terminals. Amsterdam: Elsevier; 1991.
    1. Kirakowski J, Corbett M. Measuring User Satisfaction. In: Jones DM, Winder R, editors. People and Computers IV. Cambridge: Cambridge University Press; 1988.
    1. Picard RW, Liu KK. Relative subject count and assessment of interruptive technologies applied to mobile monitoring of stress. Int J Hum Comput Stud. 2007;65:361–375.
    1. Ranney ML, Pittman SK, Dunsiger S, Guthrie KM, Spirito A, Boyer EW, Cunningham RM. Emergency department text messaging for adolescent violence and depression prevention: a pilot randomized controlled trial. Psychol Serv. 2018;15(4):419.
    1. Ranney ML, Freeman JR, Connell G, Spirito A, Boyer E, Walton M, Guthrie KM, Cunningham RM. A depression prevention intervention for adolescents in the emergency department. J Adolescent Health. 2016;59:401–410.
    1. Gold SM. Control conditions for randomised trials of behavioural interventions in psychiatry: a decision framework. Lancet Psychiatry. 2017;4(9):725–732.
    1. Robinson SM, Sobell LC, Sobell MB, Leo GI. Reliability of the timeline followback for cocaine, cannabis, and cigarette use. Psychol Addict Behav. 2014;28:154–162.
    1. Hjorthøj CR, Hjorthøj AR, Nordentoft M. Validity of timeline follow-back for self-reported use of cannabis and other illicit substances—systematic review and meta-analysis. Addictive Behaiors. 2012;37:225–233.
    1. Hesse M. The Readiness Ruler as a measure of readiness to change poly-drug use in drug abusers. Harm Reduction J. 2006;3:3.
    1. Simons JS, Gaher RM. The distress tolerance scale: development and validation of a self-report measure. Motivation Emotion. 2005;29:83–102.
    1. Strong DR, Lejuez CW, Daughters SB, Marinello M., Kahler CW, Brown RA. The computerized mirror tracing task version 1: Unpublished manual; 2003.
    1. Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988;54:1063–1070.
    1. Gratz KL, Roemer L. Multidimensional assessment of emotion regulation and dysregulation: development, factor structure, and initial validation of the difficulties in emotion regulation scale. J Psychopathol Behav Assess. 2004;36:41–54.
    1. Whiteside SP, Lynam DR. The five factor model and impulsivity: using a structural model of personality to understand impulsivity. Personality Individ Differ. 2001;30:669–689.
    1. Larsen DL, Attkisson C, Hargreaves WA, Nguyen TD. Assessment of client/patient satisfaction: development of a general scale. Evalu Program Plan. 1979;2:197–207.
    1. Kraemer HC, Mintz J, Noda A, Tinklenberg J, Yesavage JA. Caution regarding the use of pilot studies to guide power calculations for study proposals. Arch Gen Psychiatry. 2006;63:484–489.
    1. Papke LE, Wooldridge JM. Panel data methods for fractional response variables with an application to test pass rates. J Econ. 2008;145:121–133.
    1. Hall SM, Delucchi KL, Velicer WF, Kahler CW, Ranger-Moore J, Hedeker D, Tsoh JY, Niaura R. Statistical analysis of randomized trials in tobacco treatment: longitudinal designs with dichotomous outcome. Nicotine Tob Res. 2001;3:193–202.
    1. LIang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13-22.
    1. Centers for Disease Control Increases in drug and opioid overdose deaths United States, 2000–2014. Morb Mortal Wkly Rep. 2016;64:1378–1382.
    1. Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess. 2007;11:1–171.
    1. Stein MD, Cioe PA, Friedmann PD. Buprenorphine retention in primary care. J Gen Intern Med. 2005;20:1038–1041.
    1. Carroll KM, Weiss RD. The role of behavioral interventions in buprenorphine maintenance treatment: a review. Am J Psychiatry. 2017;174:738–747.
    1. Brown RA, Bloom EL, Hecht J, Moitra E, Herman DS, Stein MD. A pilot study of stress tolerance treatment for opiate dependent patients initiating buprenorphine: rationale, methodology, and outcomes. Behavior Modif. 2016;38:730–759.
    1. Leon AC, Davis LL, Kraemer HC. The role and interpretation of pilot studies in clinical research. J Psychiatr Res. 2011;45:626–629.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner